Stock Analiz

Enanta Pharmaceuticals Inc. ENTA

Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026

$10.99Market cap $320M
Open the interactive analysis →

Enanta Pharmaceuticals Inc. (ENTA) is a healthcare company listed in the US with a market value of about $320M. In the twelve months to June 30, 2026 it had revenue of $65M and net income of -$63M, a net margin of -96.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -47%.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $48M in 2014 to $65M in 2025, growth of about 2.9% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 4% over three years (dilution for shareholders). It spends 163% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.9
P/B3.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-3.4%
Revenue growth (5 yrs, per year)-11.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-137.7%
ROIC (5-yr avg.)-46.7%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$65M$65M$68M$79M$86M$97M$122M$205M$207M$103M$88M
Net income-$63M-$82M-$116M-$134M-$122M-$79M-$36M$46M$72M$18M$22M
Free cash flow-$37M-$32M-$97M-$112M-$87M-$71M$6M$66M$26M$50M$31M
EPS (diluted)$-2.42$-3.84$-5.48$-6.38$-5.91$-3.92$-1.81$2210.00$3480.00$910.00$1130.00
Net margin-96.9%-125.4%-171.6%-168.9%-141.3%-81.4%-29.5%22.6%34.8%17.2%24.6%
ROIC—-68.2%-65.1%-44.6%-35.6%-19.9%-7.1%6.2%17.3%5.4%7.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $21.83, 99% above the current price; targets range from $19.00 to $32.00; the consensus rating is “none”; expected EPS is $-2.29 for the fiscal year ending September 30, 2026.

Frequently asked questions

Does Enanta Pharmaceuticals pay a dividend?

Not currently.

Is Enanta Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Enanta Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.